We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ms
Maria
Ntessalen
+44 (0)1224 437263
elipse@abdn.ac.uk
Dr
Krishna
Narahari
+44 02920743318
krishna.narahari@wales.nhs.uk
Ms
Seonaidh
Cotton
+44 (0)1224 438178
s.c.cotton@abdn.ac.uk
Prof
Rakesh
Heer
-
r.heer@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Biopsy-proven clinically localised high-risk prostate cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Every year in the UK, nearly 50,000 people are diagnosed with prostate cancer and over 10,000 men die from it. Prostate cancer that has not spread elsewhere in the body but is at risk of doing so is referred to as high-risk localised prostate cancer. Established treatment options for high-risk prostate cancer are surgery and radiotherapy. In the UK, 4000 patients a year undergo surgery for high-risk prostate cancer. When surgeons operate on men with high-risk prostate cancer, they remove the entire prostate gland and, in some cases, also remove the nearby lymph nodes (an immune tissue that forms the early landing sites for cancer spread) in a surgery called pelvic lymph node dissection (PLND). It is thought that PLND gives better cancer clearance and reduces recurrence, which is seen in 30-50% of men with high-risk disease. However, complications can arise from PLND. These complications may reduce the quality of life, and along with the increased surgical time required, lymph node surgery in addition to removing the prostate might result in additional costs to the NHS. The study team surveyed UK surgeons and found variable practice with 35% of eligible patients getting lymph node excision. Surgeons stated that the current evidence was not good enough to inform decisions about whether it was beneficial to do a lymph node excision knowing that there are potential harms, and a clinical trial comparing lymph node excision to no lymph node excision was urgently required. This clinical trial aims to compare the two treatments in terms of their effect over 3 years on, prostate cancer recurrence, quality of life, complication rates, survival and use of NHS resources. Everyone who takes part will have an equal chance of either having their lymph nodes removed or not during their prostate cancer PCa surgery. The study will recruit 1080 patients from 25 hospitals across the UK.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Hormone therapy within the 3 months prior to consent2. Previous radical treatment for PCa (radical treatment includes radical prostatectomy and/or radiotherapy and/or focal therapy [eg cryotherapy or HIFU])3. Unsuitable for surgical treatment4. People without capacity
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Rakesh
Heer
-
r.heer@imperial.ac.uk
Ms
Seonaidh
Cotton
+44 (0)1224 438178
s.c.cotton@abdn.ac.uk
Dr
Krishna
Narahari
+44 02920743318
krishna.narahari@wales.nhs.uk
Ms
Maria
Ntessalen
+44 (0)1224 437263
elipse@abdn.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Cardiff and Vale University Health Board and funded by Health Technology Assessment Programme.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 63289
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
